TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Benitec Biopharma Inc.
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma reported positive Phase 1b/2a trial results for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy (OPMD), with a 100% responder rate. The FDA granted Fast Track Designation, and the company raised $100 million to advance the therapy's development.

Insights
NVDA   positive

Key customer for TSMC's advanced chip production, driving growth through AI and data center GPU demand


BNTC   positive

Achieved 100% responder rate in clinical trial, received FDA Fast Track Designation, successfully raised $100 million in funding, and demonstrated progress in developing a potential first-of-its-kind therapy for OPMD